Dragoni, G.Innocenti, T.Amiot, A.Castiglione, F.Melotti, L.Festa, S.Savarino, E. V.Truyens, M.Argyriou, K.Noviello, D.Molnar, T.Bouillon, V.Bezzio, C.Eder, P.Fernandes, S.Kagramanova, A.Armuzzi, A.Oliveira, R.Viola, A.Ribaldone, D. G.Drygiannakis, I.Viganò, C.Calella, F.Gravina, A. G.Pugliese, D.Chaparro, M.Ellul, P.Vieujean, S.Milla, M.Caprioli, F.2024-12-102024-12-102024-01-011873-9946http://hdl.handle.net/10400.1/26435Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is lacking, we aimed to assess the risk of complications of tofacitinib exposure prior to colectomy in comparison with anti-TNFs, vedolizumab, and ustekinumab.engconference object10.1093/ecco-jcc/jjad212.06381876-4479